Todd Brinton

Publication Details

• RevaTen platelet-rich plasma improves cardiac function after myocardial injury.

  Mishra A, Velotta J, Brinton TJ, Wang X, Chang S, Palmer O, Sheikh A, Chung J, Yang PC, Robbins R, Fischbein M. Cardiovasc Revasc Med. 2011 May-Jun; 12 (3): 158-63

  Cell therapy is an exciting area of investigation for repair of injured myocardial tissue. Platelet-rich plasma (PRP) is an autologous fractionation of whole blood containing high concentrations of growth factors including vascular endothelial growth factor and insulin-like growth factor, among many others. PRP has been shown to safely and effectively enhance healing of musculoskeletal tissue primarily by reparative cell signaling. Despite a growing body of evidence on PRP's safety and efficacy, limited studies have been performed using PRP in cardiovascular tissues. Utilizing a murine myocardial permanent ligation and ischemia/reperfusion model, this study sought to determine whether RevaTen PRP (Menlo Park, CA, USA), a proprietary formulation of PRP, improves cardiac function as measured by left ventricular ejection fraction (LVEF).

  PubMedID: 21122486